1. India Stocks

  2. •

    Consumer Defensive

  3. •

    Packaged Foods
Ajooni Biotech Limited

Ajooni Biotech Limited

AJOONI.NS
Ajooni Biotech LimitedIN flagNational Stock Exchange of India
3.88
INR
+0.07
- -
668.31MMarket Cap

Total Valuation

Ajooni Biotech Limited carries a market capitalization of 668.31M, placing it among publicly traded companies globally. Its enterprise value stands at 758.10M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap668.31M
Enterprise Value758.10M

Share Statistics

Ajooni Biotech Limited currently has 172.24M shares outstanding.

Shares Outstanding172.24M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Ajooni Biotech Limited trades at a trailing price-to-earnings ratio of 24.24. The price-to-sales ratio is 0.71, and the price-to-book ratio stands at 2.36.

PE Ratio24.24
PS Ratio0.71
PB Ratio2.36
P/TBV Ratio0.93
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, Ajooni Biotech Limited trades at an EV/EBITDA multiple of 25.99 and an EV/FCF ratio of 327.93. The EV/Sales ratio of 0.66 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 25.99 provides insight into valuation relative to core operating earnings.

EV / Sales0.66
EV / EBITDA25.99
EV / EBIT25.99
EV / FCF327.93

Financial Position

Ajooni Biotech Limited maintains a current ratio of 12.86, meaning it holds 12.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.20, indicating elevated leverage, while an interest coverage ratio of 9.75 demonstrates adequate ability to service its debt obligations.

Current Ratio12.86
Quick Ratio1.56
Debt / Equity2.20
Debt / EBITDA0.67
Interest Coverage9.75

Financial Efficiency

Ajooni Biotech Limited posts a return on equity of 12.93 and a return on invested capital of 3.30.

Return on Equity (ROE)12.93
Return on Assets (ROA)4.71
Return on Invested Capital (ROIC)3.30
Return on Capital Employed (ROCE)12.80
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover4.92

Taxes

Over the trailing twelve months, Ajooni Biotech Limited has paid 9.85M in income taxes, reflecting an effective tax rate of 22.68.

Income Tax9.85M
Effective Tax Rate22.68

Stock Price Statistics

Ajooni Biotech Limited's stock has declined approximately -33.33333% over the past 52 weeks. The 50-day moving average sits at 4.02, while the 200-day moving average is 4.42.

Beta (5Y)N/A
52-Week Price Change-33.33333%
50-Day Moving Average4.02
200-Day Moving Average4.42
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Ajooni Biotech Limited generated 1.15B in revenue and converted that into 33.59M in net income, yielding earnings per share of 0.23. EBITDA reached 29.17M, while operating income came in at 29.17M.

Revenue1.15B
Gross Profit179.57M
Operating Income29.17M
Pretax Income43.42M
Net Income33.59M
EBITDA29.17M
EBIT29.17M
Earnings Per Share (EPS)0.23

Balance Sheet

Ajooni Biotech Limited holds 75.44M in cash and equivalents against 19.40M in total debt, resulting in a net debt position of -48.90M. Total book value stands at 344.49M, with working capital of 571.83M providing operational flexibility.

Cash & Cash Equivalents75.44M
Total Debt19.40M
Net Debt-48.90M
Equity (Book Value)344.49M
Book Value Per Share2.37
Working Capital571.83M

Margins

Ajooni Biotech Limited operates with a gross margin of 15.66, reflecting its pricing power and cost economics. The operating margin of 2.54 and net profit margin of 2.93 provide insight into operational efficiency.

Gross Margin15.66
Operating Margin2.54
Pretax Margin3.79
Profit Margin2.93
EBITDA Margin2.54

Stock Splits

Ajooni Biotech Limited's most recent stock split took place on November 25, 2022 with a 500:567 split ratio.

Last Split Date11/25/2022
Split Ratio500:567

Scores

Ajooni Biotech Limited posts an Altman Z-Score of 9.05, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score9.05